Tabberer M, et al. - The purpose of this study was to examine the efficacy of once-daily triple therapy in patients with chronic obstructive pulmonary disease (COPD), with regard to patient-reported symptoms and quality of life. Findings exhibited sustained daily symptom and health-related quality of life (HRQoL) benefits of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) vs budesonide/formoterol (BUD/FOR). It was also determined that the inclusion of the COPD Assessment Test (CAT) could offer data that were readily generalizable to daily clinical practice.